Vir Biotechnology Inc (VIR) showcases progress in oncology and infectious disease programs while managing financial hurdles ...

Vir Biotechnology (NASDAQ:VIR – Get Free Report) had its target price increased by equities researchers at Barclays from ...

VIR's T-cell engagers have potential in oncology and showed promise with initial data in January 2025. Read my thoughts about ...

The programme includes the ECLIPSE 1 and ECLIPSE 2 Phase III trials, aiming to offer registrational data for regulatory ...

Vir stock catapulted by double digits. Please watch the video at Investors.com - How To Buy Stocks: IBD's Four Pillars Of Investing The company's drugs are T-cell engagers. These antibodies ...

Vir Biotechnology (VIR) announced the enrollment of the first patient in its Phase 3 ECLIPSE registrational program. The ECLIPSE registrational ...

Vir Biotechnology (NASDAQ:VIR – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at HC ...

$VIR insiders have traded $VIR stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales. Here’s a ...

Brent Sabatini, the SVP of $VIR, sold 1,562 shares of the company on 02-13-2025 for an estimated $14,291. We received data on the trade from a recent SEC filing. This ...